Regeneron leans on Dupixent while it looks for the next one

The technology

Regeneron makes fully human antibodies with its VelocImmune technology, and it says it has about 50 clinical assets. The business rests on three products: Dupixent, which it shares with Sanofi; the EYLEA eye franchise; and the cancer drug Libtayo. In the second quarter, Dupixent sales reached $6.0 billion, while US EYLEA fell 45% and EYLEA HD rose 52%.

The newer work spreads wider. The FDA approved Pasatru for the ultra-rare bone disease FOP in August. Cemdisiran, an RNAi drug against C5, is under FDA priority review in myasthenia gravis. Trevogrumab is in phase 2 to preserve muscle during GLP-1 weight loss. And the October Sanofi deal adds four long-acting type 2 inflammation antibodies meant to follow Dupixent.

The odds

Cemdisiran is the nearest regulatory event, with an FDA decision expected in November. The BIO and Informa base rate for approval once a filing is made is 90.6%.

Further back, the odds fall quickly. Trevogrumab is in phase 2, where the base rate for reaching phase 3 is 28.9%, and the COURAGE data showed muscle preservation but no added weight loss. The four new Sanofi antibodies are at or before phase 1, where the overall chance of approval is 7.9%. Fianlimab, after its phase 3 miss against pembrolizumab, now depends on a head-to-head trial against Opdualag. That trial has no disclosed readout date, and it compares fianlimab with a drug that has already beaten a PD-1 antibody alone.

Pasatru shows how the odds look in rare disease. The OPTIMA trial had only 63 patients, yet the effect was large enough to win approval, and the 84-week data showed no new lesions on treatment between weeks 56 and 84. The rare disease base rate for approval after filing is 93.6%, which fits that kind of program.

The money

Regeneron is profitable and cash rich. It reported second-quarter revenue of $4.29 billion, $17.82 billion in cash and marketable securities and $1.99 billion of long-term debt at June 30. It bought back $2.0 billion of stock in the first half and pays a $0.94 quarterly dividend. Sanofi's $1 billion upfront payment comes on top, and the repaid development balance should lift collaboration profits from the third quarter. Spending stays high. The company guided to non-GAAP R&D of $5.95 billion to $6.05 billion for 2026.

The risks

The first risk is Dupixent concentration. Regeneron does not control the drug's sales, and its patents begin to expire in 2031, according to Pharmaceutical Technology. Citi analysts said the new antibodies may not arrive before that.

The second is EYLEA erosion. The company cited continued competitive pressures for the 45% fall in US EYLEA sales, and EYLEA HD has not fully replaced the lost revenue.

The third is oncology execution. The fianlimab miss came in a 1,546-patient phase 3 trial that compared the combination with pembrolizumab in first-line melanoma.

Our read

Regeneron is a profitable antibody company in a transition between product cycles. Dupixent is still growing fast, and the settled Sanofi dispute and the end of the development balance make that stream cleaner. The weak spots are EYLEA and a cancer pipeline that has not delivered a large new win this year. Pasatru and cemdisiran show the company can still win approvals in smaller markets, but neither is likely to replace EYLEA revenue. The next markers are third-quarter results on October 30 and the cemdisiran decision in November. Over the longer run, the question is whether the Dupixent successors can reach the market before 2031.